

ASX ANNOUNCEMENT MARKET RELEASE

14 June 2023

SECONDARY TRADING NOTICE – NOTIFICATION PURSUANT TO PARAGRAPH 708A(5)(E) OF THE CORPORATIONS ACT 2001

Perth, Western Australia - Australian medical device, digital health technology company, Artrya Limited (ASX: AYA) (Artrya or the Company) provides this notice in accordance with section 708A(5)(e) of the *Corporations Act 2001* (Cth) (Corporations Act) in relation to an issue of 135,000 fully paid ordinary shares by Artrya on 14 June 2023 (Securities).

1. The Securities were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
2. As at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and section 674 of the Corporations Act.
3. As at the date of this notice, there is no excluded information (in accordance with the requirements of subsections 708A(7) and (8) of the Corporations Act).

Artrya Limited

Kevin Hart

Company Secretary

This announcement was approved and authorised for release by the Board of Artrya Limited.

For further information please contact:

Investor Enquiries:

Mathew Regan

Artrya Limited

+61 427 477 298

investors@artrya.com

About Artrya

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA). Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary artery disease and develop a holistic overview of a patient at risk. Artrya has developed deep learning algorithms that will streamline how medical care for heart disease is delivered. Artrya USA Inc. is a wholly owned subsidiary of Artrya Limited.

For more information, see www.artrya.com